LLY

1,014.25

+1.68%↑

JNJ

195.3

+1.48%↑

ABBV

232.88

+4.05%↑

UNH

339

+3.82%↑

AZN

88.24

-0.89%↓

LLY

1,014.25

+1.68%↑

JNJ

195.3

+1.48%↑

ABBV

232.88

+4.05%↑

UNH

339

+3.82%↑

AZN

88.24

-0.89%↓

LLY

1,014.25

+1.68%↑

JNJ

195.3

+1.48%↑

ABBV

232.88

+4.05%↑

UNH

339

+3.82%↑

AZN

88.24

-0.89%↓

LLY

1,014.25

+1.68%↑

JNJ

195.3

+1.48%↑

ABBV

232.88

+4.05%↑

UNH

339

+3.82%↑

AZN

88.24

-0.89%↓

LLY

1,014.25

+1.68%↑

JNJ

195.3

+1.48%↑

ABBV

232.88

+4.05%↑

UNH

339

+3.82%↑

AZN

88.24

-0.89%↓

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Open

SectorHealthcare

1.05 -3.67

Buy Sell

Overview

Share price change

24h

Current

Min

1.03

Max

1.15

Key metrics
By Trading Economics
Income	3.6M -34M
Sales	278K 1.9M
Profit margin	-1,786.576
Employees	181
EBITDA	979K -37M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+312.84% upside

Dividends
By Dow Jones
Next Earnings	17 lis 2025

Market Stats
By TradingEconomics
Market Cap	38M 145M
Previous open	4.72
Previous close	1.05

News Sentiment

By Acuity

50%

180 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

11 lis 2025, 23:59 UTC

Earnings

Singtel's 1st Half Net Profit Surges

11 lis 2025, 22:23 UTC

Acquisitions, Mergers, Takeovers

Mineral Resources Sells Stake in Lithium Mines to Posco For $765 Million

11 lis 2025, 22:21 UTC

Earnings

Aristocrat Boosts Dividend as Annual Profit Rises 12%

11 lis 2025, 23:52 UTC

Market Talk

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

11 lis 2025, 23:44 UTC

Earnings

Singtel's 1H Net Profit Surges

11 lis 2025, 23:42 UTC

Market Talk

Nikkei May Trade Rangebound Amid Caution over U.S. Econ Strength -- Market Talk

11 lis 2025, 23:18 UTC

Earnings

Singtel: Expects FY Operating Company EBIT to Grow Between High Single Digits and Low Double Digits Vs. Earlier Guidance of High Single-Digit Growth >Z74.SG

11 lis 2025, 23:15 UTC

Earnings

Singtel: Interim Dividend of 8.2 Singapore Cents per Share, up 17% >Z74.SG

11 lis 2025, 23:14 UTC

Earnings

Singtel 1H Underlying Net Profit S$1.35B, Up 14% >Z74.SG

11 lis 2025, 23:12 UTC

Earnings

Singtel 1H Net Exceptional Gain of S$2.05B >Z74.SG

11 lis 2025, 23:11 UTC

Earnings

Singtel 1H Net S$3.40B Vs. Net S$1.23B >Z74.SG

11 lis 2025, 23:10 UTC

Earnings

Singtel 1H Rev S$6.91B Vs. S$6.99B >Z74.SG

11 lis 2025, 23:04 UTC

Market Talk

RBA Will Sharply Focus On Australian Jobs Report -- Market Talk

11 lis 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

11 lis 2025, 21:50 UTC

Market Talk

Earnings

Health Care Roundup: Market Talk

11 lis 2025, 21:46 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Private Equity Can Benefit From 'Deal-Friendly' Antitrust Policies -- Market Talk

11 lis 2025, 21:41 UTC

Earnings

Aristocrat: Continues to Actively Pursue Strategic M&A Opportunities

11 lis 2025, 21:40 UTC

Earnings

Aristocrat: Expects to Deliver Npata Growth Over FY 2026 on a Constant Currency Basis

11 lis 2025, 21:39 UTC

Earnings

Aristocrat: Interactive Delivered Revenue Growth Mainly Due to Inclusion of NeoGames

11 lis 2025, 21:39 UTC

Earnings

Aristocrat: Key Social Casino Franchises Continued to Outperform Market

11 lis 2025, 21:39 UTC

Earnings

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

11 lis 2025, 21:38 UTC

Earnings

Aristocrat: FY Normalized Npata Up 9% in Constant Currency

11 lis 2025, 21:38 UTC

Earnings

Aristocrat: Final Dividend 49 Australian Cents/Share

11 lis 2025, 21:37 UTC

Earnings

Aristocrat: FY Statutory Net Profit from Continuing Ops A$1.18 Bln, Up 2.9%

11 lis 2025, 21:36 UTC

Earnings

Aristocrat: FY Normalized Operating Revenue A$6.3 Bln, Up 11%

11 lis 2025, 21:35 UTC

Earnings

Aristocrat: FY Normalized Npata A$1.55 Bln, Up 12.2%

11 lis 2025, 21:35 UTC

Earnings

Alcon 3Q Adj EPS 79c >ALC

11 lis 2025, 21:35 UTC

Earnings

Alcon 3Q Rev $2.61B >ALC.EB

11 lis 2025, 21:35 UTC

Earnings

Alcon Backs 2025 EPS $3.05-EPS $3.15 >ALC.EB

11 lis 2025, 21:35 UTC

Earnings

Alcon 3Q EPS 48c >ALC.EB

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

312.84% upside

12 Months Forecast

Average 4.5 USD 312.84%

High 7 USD

Low 2 USD

Based on 9 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

180 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.